29 rue Tronchet
About Vivet TherapeuticsVivet Therapeutics is a gene therapy biotech company with headquarters in Paris, France, dedicated to the research, development and future commercialization of gene therapy treatments for inherited liver disorders with high medical need.
Co-Founder & CEO: Jean-Philippe COMBAL, PharmD, Ph.D
Co-Founder & CSO: Dr. Gloria Gonzalez-Aseguinolaza
Co-Founder & Chief Development Officer: Dr. Jens Kurth
CMO: Bernard Bénichou, M.D., Ph.D
General Counsel and Head of Finance: Susan Coles
Please click here for Vivet's scientific approach.
7 articles with Vivet Therapeutics
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet Therapeutics and Pfizer Inc. announced that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and potentially life-threatening liver disorder.
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation
Vivet Therapeutics announced that both the Food and Drug Administration and the European Commission have granted Orphan Drug Designation for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3.
Vivet Therapeutics Announces 2 Abstracts Accepted for Oral Presentation at 2019 American Society of Gene and Cell Therapy Annual Meeting
Compelling additional preclinical data further support therapeutic potential of gene therapy products to treat Wilson disease (WD) and Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3).
Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease
Eduardo Bravo takes over from Dr. Florent Gros who served as Chairman since the creation of Vivet Therapeutics.
Vivet Therapeutics’s First Gene Therapy Product, Vtx 801 For Wilson’s Disease, Receives European And Us Orphan Drug Designation